🇺🇸 FDA
Patent

US 12161696

Methods of treating hemophilic arthropathy using chimeric clotting factors

granted A61KA61K38/37A61K38/4846

Quick answer

US patent 12161696 (Methods of treating hemophilic arthropathy using chimeric clotting factors) held by BIOVERATIV THERAPEUTICS INC. expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/37, A61K38/4846, A61P, A61P19/02